Poor Demand for Its Covid Vaccine Prompts Novavax to Cut Sales Forecast
Novavax Inc.
slashed its full-year revenue outlook in half on Monday, citing a lack of demand for its Covid-19 vaccine from an international initiative to vaccinate lower-income countries and delays in winning expanded authorizations in the U.S. The new guidance reflects an unexpected shortfall in demand for Covid-19 vaccines, Novavax Chief Executive
Stanley Erck
said in an interview. Covax, the international vaccine initiative, has backed away from an order of…